Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Stalevo 200 vs Sinemet on striatal 11C-raclopride binding in Parkinson's disease with wearing-off
2007-002496-14Phase 2Terminated
- Sponsor
- Orion Corporation
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of levodopa in Parkinson's disease (PD) (2 arms), sponsored by Orion Corporation. Primary endpoint: Change in striatal 11C-raclopride binding potential. Started Sep 2007; status: terminated.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2007-002496-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002496-14.